SinoCellTech (SHA: 688520) has received regulatory approval in China for finotonlimab, making it the first immuno-oncology ...
A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback